We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Clinical Trial Medical-Image Collect-and-Hold System Centralizes Imaging Data

By LabMedica International staff writers
Posted on 20 Aug 2009
A new image management solution has been designed to collect and hold medical images in clinical trials, called iMAS (image management archive system). More...
The iMAS is a cost-effective option for clinical trial sponsors to centralize the collection of the large imaging data sets frequently utilized in clinical trials, while giving them accessibility and secure storage, with minimal investment.

The system was developed by M2S, Inc. (West Lebanon, NH, USA), a global provider of image management services for biopharmaceutical and medical device clinical trials. M2S offers cost-effective medical image management solution for clinical trial sponsors.

"Clinical trial sponsors are facing extraordinary cost pressures in the current economy,” said Wes Chapman, CEO of M2S. "With less time needed for setup, decreased trial complexity, and reduced documentation requirements, an M2S iMAS trial is typically only 20% of the cost of a full clinical trial. This option gives trial sponsors the control and flexibility to adjust a trial and add a blinded radiological review at any point, while simultaneously containing costs.”

While many clinical trials continue to incorporate imaging data for surrogate endpoints, it is not always clear whether image data review and submission will be necessary. However, potentially valuable and expensive imaging data can and probably should still be collected. Sponsors may want to consider using those images for a later submission, subsequent trials or for patient registries, and the risk, cost, and effort of retrospectively collecting images can exceed that of prospective medical image collection.

M2S will customize the iMAS product based on service levels needed for a particular clinical trial--including consultation, project management, and query management. Real-time, web-based reports allow sponsors to see both the status of data gathered as well as access the data anytime, anywhere.

M2S provides medical image data management services across the healthcare continuum based on best-in-class technology and continuous quality improvement processes. M2S clinical trial image-management services include protocol development, electronic image collection, independent review, archive, and real-time web-based data access. M2S clinical data registries provide long-term evaluation of treatment outcomes, benefits, and cost.

Related Links:
M2S


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.